Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
' t+ ^9 D0 p6 [3 l* o( G4 {, |7 B. z) {' p; ?- j4 z3 T+ J
* T' N4 o% A, ^# H+ iSub-category:
! f4 G2 w+ P! Q3 a m0 ]: GMolecular Targets 7 T [9 A( U! G, |% @
3 ~% a3 h; b. s
8 i8 {& ]; T/ R% i: YCategory:
, [, q2 B1 y# ~3 A' ^2 ~Tumor Biology
) t/ ]. m5 A" T
+ R4 c3 R* _0 A; G# V# p' U" K2 Q+ u; {4 x% ~
Meeting:- V# [% N* K) D7 R
2011 ASCO Annual Meeting
% o/ F( ~' T( ? G
" `0 G' Z& t& c
F: A( h5 I, d2 h; D9 o ^( qSession Type and Session Title:# Z9 q' \& i8 L% V. Z( m
Poster Discussion Session, Tumor Biology
4 ]6 _2 F# q; L
' w% J. }* W- L: K6 Y. S# d
6 i, O& y2 Z4 P8 }8 x* YAbstract No:
: D$ b9 X# F" S5 V0 t9 f10517
; Q3 u4 W, }( e( l8 Z
6 T' U ]/ u. Y' O) K3 T* D4 f5 z3 Q% @" M
Citation:) |2 e$ T2 v- [8 [! G; h3 j C- x
J Clin Oncol 29: 2011 (suppl; abstr 10517)
5 D1 S4 n, Y) z- d
7 j& j' j. t' P8 o8 E7 r. N; D& |( @% l6 [) B: z5 [
Author(s):( M2 U6 {2 L8 W
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China % T, L3 r& k3 v6 f# V+ U: t: ^
' T; v5 `5 K' Q6 b6 R. n' l5 j/ h7 G5 l7 }+ D2 J! i
' s! X3 G$ ?' |+ p* G! kAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 h, n% O: r& ?- t& D& g7 U) m( v$ A/ \- ]5 ~) D
Abstract Disclosures
' T: W9 Y# u) S' `( q7 d5 z6 `7 B5 N( S; e Y
Abstract:
' v9 V! @1 R( W* d$ r$ @/ t! B3 B' b, j- f4 C2 |1 k c b
4 z$ z" A- j9 T4 X2 V0 f& pBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# ]6 w/ z7 n: X y E- R" A" M2 l- c3 ~
% Y2 S# N7 r* Q- c: g
, n7 l6 N: J, f+ |! ?1 s9 h |
显身卡
